TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Value of Tranxemic Acid to Reduce Intraoperative Blood Loss During Elective Cesarean Sections in High Risk Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Grand multipara~  * Multiple pregnancy~ * Polyhydraminos (AFI is more than 24 cm).~ * Placenta previa~ * Gestational diabetes mellitus~ * Preeclampsia~ * Anemia complicating pregnancy (Hemoglobin is less than 11 gm/dl)~Exclusion Criteria:~* • Allergy to tranxemic acid.~  * H/o suggestive of bleeding disorders~ * previous history of deep vein thrombosis~ * Abnormally invasive placenta~ * Emergency cesarean sections~ * Intraoprative complications during cesarean sections as uterine artery injury and broad ligamentary hematoma.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid group (Type: ACTIVE_COMPARATOR): 1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
- Control group (Type: PLACEBO_COMPARATOR): 30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients~* Newly diagnosed with OSA who are prescribed CPAP therapy~Exclusion Criteria:~* Patients \< 18 years old~* Patients over 65 years~* Pregnant women~* Patients with chronic liver disease~* Patients who abuse alcohol~* Patients taking narcotics or using sedative-hypnotic agents such as Ambien, Klonopin or Benadryl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- OSA CPAP (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus, type 1~* Levels of HbA1C (glycated hemoglobin) \<7.4% (NGSP standard)~* Levels of HbA1C \>8.4% (NGSP standard)~Exclusion Criteria:~* Prior aspirin treatment~* Treatment with anticoagulant drugs~* Ongoing treatment with NSAIDs or other antiplatelet drugs~* A history of macrovascular disease

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin 75mg (Type: ACTIVE_COMPARATOR): None
- Aspirin 320mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Wears a removable bilateral mandibular partial denture that has good stability and support, with sufficient room on each side in the posterior buccal flange area to accommodate two enamel specimens \[required dimensions 12 x 7 millimeters (mm)\].

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- CSP/SMFP Dentifrice (Type: EXPERIMENTAL): Dentifrice containing high fluoride content as SMFP and CSP
- SMFP Dentifrice Prototype 1 (Type: ACTIVE_COMPARATOR): Dentifrice containing high fluoride content as SMFP and no CSP
- SMFP Dentifrice Prototype 2 (Type: ACTIVE_COMPARATOR): Dentifrice containing low fluoride content as SMFP and no CSP
- CSP Dentifrice (Type: ACTIVE_COMPARATOR): Dentifrice containing CSP but no fluoride
- Placebo Dentifrice (Type: PLACEBO_COMPARATOR): Dentifrice containing no CSP and no fluoride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for at least 12 months~* Current treatment with any basal/bolus regimen or any biphasic insulin treatment for at least 6 months~* BMI below or equal to 35 kg/m\^2~* HbA1c below or equal to 12%~Exclusion Criteria:~* Proliferative retinopathy or maculopathy requiring acute treatment~* Recurrent major hypoglycaemia that may interfere with trial participation (as judged by the Investigator)~* Subjects with known hypoglycaemic unawareness as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Basal/bolus regimen 1 (Type: EXPERIMENTAL): None
- Basal/bolus regimen 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 18 and 55 years of age.~2. History of perennial allergic rhinitis.~3. Positive skin test to dust mite, dog, cat or indoor mold antigen.~4. And a combined nasal morning and evening score of ≥4 for nasal congestion in the day preceding entry~Exclusion Criteria:~1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~2. Pregnant or lactating women.~3. Subjects treated with systemic steroids during the previous 30 days.~4. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.~5. Subjects treated with oral antihistamine/decongestants during the previous seven days.~6. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.~7. Subjects treated with immunotherapy and are escalating their dose.~8. Subjects on chronic anti-asthma medications.~9. Subjects with polyps in the nose or a significantly displaced septum.~10. Upper respiratory infection within 14 days of study start.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo FF + Placebo OXY (Type: PLACEBO_COMPARATOR): Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
- FF + Placebo OXY (Type: ACTIVE_COMPARATOR): Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
- Placebo FF + OXY (Type: ACTIVE_COMPARATOR): Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
- FF + OXY (Type: ACTIVE_COMPARATOR): Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men and women over 18 years of age~2. DSM IV-TR criteria for OCD~3. OCD associated with most distress or most interference in the patient's life as judged by the treating physician~4. Yale-Brown Obsessive Compulsive Scale (YBOCS) total score ≥ 16~Exclusion Criteria:~1. Other primary or co-primary psychiatric disorder which is more distressful for the patient then the OCD, as evaluated by investigator~2. Patients with any history of mania/bipolar disorder~3. Patients using medications which are contraindicated with the use of escitalopram~4. Known contraindication for the use of citalopram or escitalopram.~5. Unable to understand and give informed consent~6. Prominent suicidal ideation (2 points or more in the MADRS suicidal thoughts item)~7. Alcohol or substance dependence in the past 6 months~8. Major physical illness~9. Woman currently pregnant or less then 4 weeks after a childbirth, a woman lactating, or a woman of childbearing potential not using a medically accepted form of contraception.~10. Liver function abnormality~11. EKG abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in good health~* Subject has been a nonsmoker for at least 6 months~* Subject is willing to avoid strenuous activity from the screening visit until the end of the study~* Subject agrees not to consume grapefruit products during the study and to avoid all fruit juices 24 hours before and after study drug administration~Exclusion Criteria:~* Any history of stroke or neurological disorder~* Subject has a history of cardiovascular, blood, endocrine or liver diseases~* Subject has a history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Sitagliptin alone
- B (Type: ACTIVE_COMPARATOR): Metformin alone
- C (Type: EXPERIMENTAL): Sitagliptin and metformin concomitantly
- D (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pneumococcal Conjugate Vaccine (PCV) in HIV- Infected Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV - infected children~   * HIV infected individuals~  * Age between 2 months to 9 years~  * Signed written informed consent~2. HIV - exposed negative children~   * Maternal HIV infection, documented prior to delivery.~  * Age between 2 months to 9 years~  * Signed written informed consent~Exclusion Criteria:~* Active opportunistic infection~* History of hypersensitivity to pneumococcal conjugate vaccine or diphtheria toxoid~* Using oral steroid or immunosuppressive drugs~* Received pneumococcal conjugate vaccine, or pnuemococal polysaccharide vaccine

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): Receive valent pneumococcal conjugated vaccine in HIV - infected children
- 2 (Type: OTHER): Receive valent pneumococcal conjugated vaccine in HIV negative children

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral primary total hip arthroplasty by Dr. James Verner at Beaumont Hospital Royal Oak~* Have a diagnosis of primary osteoarthritis (i.e. degenerative joint disease)~* Surgical approach is anterior~Exclusion Criteria:~* Minors (age less than 18 years)~* Pregnant (surgically sterile, post-menopausal, or negative blood test)~* Previous ipsilateral hip surgery~* Lumbar instrumentation~* Acute trauma~* Rheumatoid arthritis~* Avascular necrosis~* Hip dysplasia~* Known sensitivity, allergy, or contraindication to anesthetics being used in the study~* Narcotic sensitivity~* History of over 6 months of opioid dependency prior to surgery (excluding tramadol)~* Peripheral neuropathy~* Mental/cognitive impairment that would interfere with the patient's self-assessments of function, pain, or quality of life

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Psoas Compartment Block (Type: EXPERIMENTAL): After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
- Periarticular Local Anesthetic (Type: ACTIVE_COMPARATOR): An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to sign consent form~* Naïve to ART (remote ART use \>5 years will be considered on a case by case basis)~* No known GI or cardiovascular disease~* Between the ages of 18 and 60~* No active opportunistic infections or therapy for acute OI within 30 days of entry. Subjects can be on secondary prophylaxis with a history of AIDS defining illness.~* All women of childbearing potential (WCBP) must have a negative urine pregnancy test before any of the invasive or radiation exposure study procedures.~* Normal population should be free of chronic metabolic conditions such as diabetes, hypercholesterolemia, or coronary artery disease~* There are no CD4+ T-cell count or HIV plasma viral load restrictions.~Exclusion Criteria:~* Abnormal coagulation parameters (PT\>1.2 upper limit of normal (ULN))~* Thrombocytopenia (platelet count \<50.000 within 6 weeks)~* Contra-indications to upper endoscopy or conscious sedation~* Anemia (\>grade 1 \[appendix 1\])~* Aspirin, ibuprofen, warfarin or other agents that interfere with the coagulation cascade are prohibited within 1 week of endoscopy.~* Renal insufficiency (serum Creatinine \>1.2 ULN)~* History of chronic proteinuria that could impact viread use.~* Allergy to contrast used for CT angiography~* Requirement to take medications that are contraindicated with study ART regimen.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HIV positive naive to ART (Type: ACTIVE_COMPARATOR): HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
- normal control volunteers (Type: NO_INTERVENTION): HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age 18 years or older~2. Histologically confirmed diagnosis of MZL including splenic, nodal, and extranodal subtypes~3. Previously received one or more lines of therapy including at least one CD20-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least partial response or documented progressive disease (PD) after, the most recent systemic treatment~4. Current need for systemic therapy for MZL~5. Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)~6. Eastern Cooperative Oncology Group (ECOG) of 0-2~7. Life expectancy ≥ 6 months~8. Adequate bone marrow function~9. Adequate organ function~10. Male and female participants must use highly effective methods of contraception~Key Exclusion Criteria:~1. Known transformation to aggressive lymphoma, eg, large cell lymphoma~2. Clinically significant cardiovascular disease~3. Prior malignancy within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer~4. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention~5. History of stroke or intracranial hemorrhage~6. Severe or debilitating pulmonary disease~7. Active fungal, bacterial and/or viral infection requiring systemic therapy~8. Known central nervous system involvement by lymphoma~9. Known infection with HIV, or serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection~10. Major surgery within 4 weeks of the first dose of study drug~11. Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor~12. Pregnant or lactating women~13. Requires ongoing treatment with a strong Cytochrome P4503A (CYP3A) inhibitor or inducer~14. Concurrent participation in another therapeutic clinical trial~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zanubrutinib (Type: EXPERIMENTAL): Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects with relapsing remitting MS.~* Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy.~* Patients who had been previously on 2nd line therapies. It was understood that these patients satisfied the above mentioned criteria listed under a. in the past.~This also included patients, who were previously treated with fingolimod (regardless of whether or not they had already been treated within the START study) but discontinued treatment due to medical reasons.~- or patients with rapidly evolving severe RRMS (e.g. \> 2 relapses with disease progression in one year and \> 1 Gd-enhancing lesion or with a significant increase in T2 lesions compared to a recent MRI).~Key Exclusion Criteria:~* immunocompromised patients~* active infections~* pregnant or nursing women, women of childbearing potential unless using 2 reliable forms of contraception~* presence of malignancy (other than localized basal cell carcinoma of the skin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fingolimod (Type: EXPERIMENTAL): Fingolimod 0.5 mg by mouth once daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete